Agios Pharmaceuticals (AGIO) shares ended the last trading session 18.6% higher at $29.17. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 13.5% loss over the past four weeks.The stock rallied after the company announced that the FDA has approved Aqvesme (mitapivat) for the treatment of adult patients with alpha- or beta-thalassemia. With this approval, Aqvesme became the only FDA-approved drug for the treatment of ...